Moody’s lifts Genmab outlook to positive on pipeline progress, debt reduction
Summary
Rating agency Moody's has revised its outlook for biotechnology company Genmab to positive. This upward adjustment follows recent advancements in the firm's drug development pipeline alongside successful efforts to lower its overall debt.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.